

**FACSIMILE MESSAGE**Original Will Follow Via:

- | | |
|----------------------------------|--|
| <input type="checkbox"/> Mail | <input type="checkbox"/> International Airmail |
| <input type="checkbox"/> Courier | <input type="checkbox"/> Hand Deliver |
| <input type="checkbox"/> Fed Ex | <input checked="" type="checkbox"/> Will <u>Not</u> Follow |

Confidentiality Notice

The documents accompanying this facsimile transmission contain CONFIDENTIAL information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us. Any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited.

| | |
|-------------------|---------------------------------|
| Attention: | SISSON, BRADLEY L |
| Fax: | +1 703 746 5020 |
| Sender: | Carin Ribard |
| Company: | GENSET |
| Telephone: | +33 1 55 04 59 66 |
| Fax: | +33 1 55 04 59 31 |
| Date: | 14 August 2002 |
| Pages: | 6 (including cover page) |

Sir :

Please find enclosed a Supplemental Response to Restriction/Election Requirement And Preliminary Amendment in Appl. No. 09/731,872.

Yours Sincerely,

Carin Ribard.

Patent Engineer

You should receive a total of 6 page(s), including this cover sheet. If you do not receive all the pages, please call the number above

Supp Grant
13

Ref. No. 78.US3.REG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Applicant : Dumas Milne Edwards et al.

Appl. No. : 09/731,872

Filed : December 7, 2000

Title : FULL-LENGTH HUMAN CDNAS
ENCODING POTENTIALLY SECRETED
PROTEINS

Grp./A.U. : 1634

Examiner : Sisson, Bradley L

Official
8-14-02
G.J.F.Honorable Commissioner of Patents
Washington, D.C. 20231SUPPLEMENTAL RESPONSE TO RESTRICTION/ELECTION REQUIREMENT
AND PRELIMINARY AMENDMENT

Sir:

In response to the Restriction Requirement mailed June 13, 2002, in the above-identified application, Applicants elect Group V, drawn to polypeptides, with traverse. Applicants further elect the polypeptide of SEQ ID NO: 253. Additionally, Applicants respectfully request the Examiner enter the following amendment prior to examination of the application on the merits:

In the Claims:

Please cancel claims 30-36.

Please add new claims 37-36 as follows:

37. (NEW) A purified and isolated polypeptide comprising an amino acid sequence of a mature polypeptide sequence of SEQ ID NO: 253.

38. (NEW) The polypeptide of Claim 30, wherein said polypeptide comprises an amino acid sequence of a full-length polypeptide sequence of SEQ ID NO: 253.

39. (NEW) The polypeptide of Claim 30, wherein said polypeptide consists of an amino acid sequence of a mature polypeptide sequence of SEQ ID NO: 253.

40. (NEW) The polypeptide of Claim 31, wherein said polypeptide consists of an amino acid

Sub C1
B1